CClinicalTrials.gg
CompletedNCT02190071EUS-FNAUpdated May 27, 2016

Comparison Between Base and Cover Slide From Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer

An observational study in Pancreatic Cancer, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Per ClinicalTrials.gov, last updated 2016-05-27.

Sponsored by Seoul National University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
73
Sex
All
01

Study summary

The purpose of this study is to determine whether there is a difference of diagnostic accuracy between cover slides and base slides from EUS-FNA cytopathologic sample in patients who were previously suspected of pancreatic cancer in radiologic test.

Read the detailed description
  1. background

    1. Pancreatic cancer is the challenging malignancy in diagnosis and treatment.
    2. Recently, EUS-FNA has played a important role in diagnosing pancreatic cancer.
    3. Samples from EUS-FNA are sent to following three types of preparations.

      • cytologic smear (by pull apart method)
      • cell block
      • histologic biopsy
    4. In cytologic smear method, endoscopists tend to send as many as slides, while pathologists want minimal slides if they warrant diagnostic accuracy.
    5. Therefore we are going to find a point of contact between high diagnostic yield and minimal overloading of pathologist.
  2. Method

    1. We are going to enrolled the patients who were suspected of pancreatic cancer in previous radiologic test.
    2. One identical and skilled endoscopist performs EUS-FNA with multiple punctures.
    3. We get total 8 pairs of slides (= 8 covers + 8 bases).
    4. All the cover slides are collected to the bottle-A, all the base slide to the bottle-B.
    5. One identical and skilled pathologist inspects these slide in blind method. (She cannot show the label of bottle so that she does not know what bottle is A or B.)
    6. She record the positive or negative in each bottle. (If there is only one slide is positive in malignant cell, the bottle is positive.)
    7. In these manner, we collect the all subjects' cytopathologic results as a pair of outcome. All the possible combinations are following four examples:

      • (cover/base) = (positive/positive) = (+/+)
      • (cover/base) = (positive/negative) = (+/-)
      • (cover/base) = (negative/positive) = (-/+)
      • (cover/base) = (negative/negative) = (-/-)
    8. Then we are going to take a two-sided non-inferiority test of proportion using McNemar's test.
02

Conditions studied

  • Pancreatic Cancer

Keywords

  • EUS-FNA
  • cytopathology
  • slide smear
03

In context

Pancreatic Neoplasms

3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.

This study's enrollment of 73 is below the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients who visited to tertiary medical center(Seoul National University Bundang Hospital) because of suspicious pancreatic cancer in radiologic study

Inclusion criteria

  • patients who were suspected of pancreatic cancer in previous radiologic test such as computed tomography, magnetic resonance imaging or Positron Emission Tomography.

Exclusion criteria

Exclusion Criteria:

  • failed smear due to inexperienced assistant
  • loss of slide
  • patients who were diagnosed with other lesion far from pancreatic cancer in prospective confirmative tests.
  • patients who refuse to participate in this study
  • report of other pathologist who are not a previously-assigned pathologist
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
73 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. positive malignancy rate of cover slides set and base slides set.

    comparison between diagnostic accuracy between cover slide sets and base slide sets

    Time frame: cytopathological report within 2 weeks after EUS-FNA

Secondary outcomes

  1. positive malignancy rate of (1) cytologic smear, (2) cell block and (3) histologic biopsy

    comparison of three types of test in rate of positive malignancy

    Time frame: record of pathologist within 2 weeks after EUS-FNA

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggi-do 463-707, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02190071
Lead sponsor
Seoul National University Hospital
Responsible party
Sponsor
First posted
Jul 15, 2014
Start date
Jun 2014
Primary completion
Mar 2016
Completion
Mar 2016
Last update
May 27, 2016

Study contacts

Jaihwan Kim, M.D.
study chair · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion